Ternary nanoparticle complex of ciprofloxacin exhibiting sustained release at gastric pH prepared by co-complexation with polyanions and an ionic amphiphile
Source abstract
Abstract
Abstract Poor bioavailability of the broad spectrum antibiotic ciprofloxacin (CIP) is caused by its narrow absorption window in the stomach. With the aim of prolonging the gastric residence time of CIP, we prepared a ternary nanoparticle complex (nanoplex) of CIP by co-complexation with polyanions (sodium dextran sulfate (DXT)) and an anionic amphiphile (sodium dodecyl sulfate (SDS)). We investigated the effect of the charge ratio of DXT to SDS on the size, zeta potential, CIP payload, and CIP utilization rate of the CIP-DXT-SDS nanoplex and its dissolution characteristics in simulated gastrointestinal fluids. Fourier transform infrared spectroscopy, powder X-ray diffraction, and differential scanning calorimetry analyses showed that the ternary nanoplex was made up of amorphous CIP-DXT and crystalline CIP-SDS complexes. The size of the CIP-DXT-SDS nanoplex prepared at a > 90% CIP utilization rate was 110–290 nm and it had a zeta potential of −16–39 mV, and CIP payload of 47–62%, depending on the charge ratio. At gastric pH, the CIP-DXT-SDS nanoplex prepared with a DXT:SDS charge ratio lower than 80:20 exhibited prolonged CIP release (60% dissolution after 8 h) compared with native CIP (100% dissolution after 1 h) and a binary CIP-DXT nanoplex (80% dissolution after 5 h), which was attributed to its lower solubility. The sustained release characteristics of the CIP-DXT-SDS nanoplex were comparable to those of existing CIP gastroretentive formulations.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems · Membrane Separation and Gas Transport
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (34)
Show source-provided references
1. Formulation and evaluation of swellable and floating gastroretentive ciprofloxacin hydrochloride tablets10.1208/s12249-009-9200-y ↗
2. Infrared multiple photon dissociation spectroscopy of ciprofloxacin: Investigation of the protonation site10.1016/j.chemphys.2011.05.018 ↗
3. Solubility of antibiotics in different solvents. Part II. Non-hydrochloride forms of tetracycline and ciprofloxacin10.1021/ie8003495 ↗
4. Ciprofloxacin hippurate salt: Crystallization tactics, structural aspects, and biopharmaceutical performance10.1021/acs.cgd.6b00533 ↗
5. Assessment of solubilization characteristics of different surfactants for carvedilol phosphate as a function of pH10.1016/j.jcis.2009.03.047 ↗
6. The influence of 1-butanol and trisodium citrate ion on morphology and chemical properties of chitosan-based microcapsules during rigidification by alkali treatment10.3390/md12125801 ↗
7. Self-assembled amorphous drug-polyelectrolyte nanoparticle complex with enhanced dissolution rate and saturation solubility10.1016/j.jcis.2011.10.011 ↗
8. Production and evaluation of dry alginate-chitosan microcapsules as an enteric delivery vehicle for probiotic bacteria10.1021/bm200576h ↗
9. Formulation strategies for absorption windows10.1016/S1359-6446(04)03351-3 ↗
10. Colloidal polyelectrolyte complexes of chitosan and dextran sulfate towards versatile nanocarriers of bioactive molecules10.1016/j.ejpb.2010.12.001 ↗
11. An in silico approach to determine challenges in the bioavailability of ciprofloxacin, a poorly soluble weak base with borderline solubility and permeability characteristics10.1016/j.ejpb.2017.10.019 ↗
12. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the HF-capsule10.1111/j.1365-2125.1990.tb03740.x ↗
13. An overview of the different excipients useful for the direct compression of tablets10.1016/S1461-5347(99)00237-0 ↗
14. Re-evaluating the presumed superiority of amorphous nanoparticles over amorphous microscale solid dispersion in solubility enhancement of poorly soluble drugs10.1016/j.ejps.2017.09.010 ↗
15. Preparation and characterization of amorphous ciprofloxacin-amino acid salts10.1016/j.ejpb.2017.09.009 ↗
16. Amorphous polymeric drug salts as ionic solid dispersion forms of ciprofloxacin10.1021/acs.molpharmaceut.7b00039 ↗
17. Polymer/amorphous salt solid dispersions of ciprofloxacin10.1007/s11095-017-2250-z ↗
18. Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: Pharmacokinetic characterization in healthy human volunteers10.1016/j.ijpharm.2011.02.035 ↗
19. Absorption sites of orally administered drugs in the small intestine10.1080/17460441.2017.1378176 ↗
20. Biowaiver monographs for immediate release solid oral dosage forms: Ciprofloxacin hydrochloride10.1002/jps.22259 ↗
21. Formation and physicochemical properties of crystalline and amorphous salts with different stoichiometries formed between ciprofloxacin and succinic acid10.1021/mp400127r ↗
22. Analysis of nanofluid flow in a porous media rotating system between two permeable sheets considering thermoporetic and Brownian motion
23. Numerical optimization of microchannel heat sink (MCHS) performance cooled by KKL based nanofluids in saturated porous medium10.1016/j.jtice.2015.04.016 ↗
24. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: In vitro and in situ inhibition studies10.1016/S0939-6411(02)00185-6 ↗
25. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery10.1016/0378-5173(96)85200-8 ↗
26. Pharmaceutical salts of ciprofloxacin with dicarboxylic acids10.1016/j.ejps.2015.06.004 ↗
27. Impact of viscosity variation on oblique flow of Cu-H2O nanofluid10.1177/0954408917732759 ↗
28. Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: Development, optimization and in vitro-in vivo evaluation in healthy human volunteers10.1016/j.ejpb.2009.11.010 ↗
29. Crystal structure of ciprofloxacin hexahydrate and its characterization10.1016/S0378-5173(97)04913-2 ↗
30. Counter-ion complexes for enhanced drug loading in nanocarriers: Proof-of-concept and beyond10.1016/j.ijpharm.2016.08.004 ↗
31. Formulation and in vitro characterization of ciprofloxacin floating and bioadhesive extended-release tablets10.1080/10717540500395106 ↗
32. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds10.1016/j.ejpb.2005.03.002 ↗
33. Ciprofloxacin permeability and its active secretion through rat small intestine in vitro10.1016/j.ijpharm.2006.02.004 ↗
34. Salt screening and characterization of ciprofloxacin10.1107/S2052520615018582 ↗